KEYNOTE-427 (Cohort A): Phase II Study of Pembrolizumab Monotherapy for First-line Treatment of Patients With Advanced Clear-Cell Renal Cell Carcinoma

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: April 18, 2022 Expired: April 17, 2023

Commentary with expert answers to healthcare professional questions on adjuvant therapy for renal cell carcinoma, from Clinical Care Options (CCO)

Brian A. Costello, MD, MS Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: April 13, 2022

Commentary with expert answers to healthcare professional questions on therapy for metastatic renal cell carcinoma, from Clinical Care Options (CCO)

Brian A. Costello, MD, MS Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: April 13, 2022

Downloadable slideset from Dr. Brian Costello on adjuvant approaches and first line treatment options for patients with RCC, from Clinical Care Options (CCO).

Brian A. Costello, MD, MS Released: March 1, 2022